Glaukos Corporation (GKOS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Glaukos Corporation (GKOS) Healthcare & Pipeline Overview

Glaukos Corporation is a specialized ophthalmic medical technology and pharmaceutical firm advancing therapies for glaucoma, corneal, and retinal diseases. The company leverages its iStent micro-bypass stents and a robust pipeline, including iStent Infinite and iDose TR, to address significant unmet needs in eye care, positioning itself within the evolving medical device and pharmaceutical landscape.

What Is the Investment Thesis for GKOS?

Glaukos Corporation presents an investment profile centered on its innovative ophthalmic medical technology and pharmaceutical pipeline, targeting significant unmet needs in glaucoma, corneal, and retinal diseases. The company's established iStent product family, designed for mild-to-moderate open-angle glaucoma, underpins its current market position, evidenced by a robust Gross Margin of 78.1%. Future growth is anticipated from the commercialization of pipeline assets such as iStent Infinite, aimed at the refractory glaucoma market, and iDose TR, a sustained-release drug delivery system with potential to revolutionize treatment adherence and efficacy. While the company currently operates with a Profit Margin of -34.3% and a Return on Equity (ROE) of -26.4%, indicating a focus on R&D and market penetration over immediate profitability, its positive Free Cash Flow of $0.01B suggests operational cash generation. A Debt-to-Equity ratio of 15.78 indicates a relatively low reliance on debt financing. The company's Beta of 0.95 suggests its stock exhibits similar volatility to the broader market, making its performance closely tied to overall market sentiment and sector-specific developments. Continued pipeline success and market adoption are critical for realizing long-term value.

Based on FMP financials and quantitative analysis

GKOS Key Highlights

Gross Margin of 78.1% indicates strong profitability on products sold, reflecting the value and pricing power of its specialized ophthalmic devices.

• Market Capitalization of $10.1B positions Glaukos as a significant player within the ophthalmic medical technology sector.
• Negative Profit Margin of -34.3% and Return on Equity (ROE) of -26.4% reflect substantial ongoing investments in research and development and market expansion efforts.
• Debt-to-Equity ratio of 15.78 suggests a conservative capital structure with relatively low leverage compared to equity.
• Positive Free Cash Flow (FCF) of $0.01 billion indicates the company is generating cash from its operations, providing flexibility for future investments despite negative net income.

Who Are GKOS's Competitors?

GKOS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GKOS's Key Strengths?

Pioneering position in the Minimally Invasive Glaucoma Surgery (MIGS) market with established iStent products.

• Strong gross margin of 78.1% reflecting efficient production and value of proprietary technology.
• Robust product pipeline targeting significant unmet needs in refractory glaucoma and sustained drug delivery.
• Global commercial reach through direct sales and international distributors.
• Positive free cash flow despite overall negative profitability, indicating operational efficiency.

What Are GKOS's Weaknesses?

Currently operating at a negative profit margin (-34.3%) and negative return on equity (-26.4%), indicating unprofitability.

• Significant reliance on pipeline success for future growth, which carries inherent development and regulatory risks.
• Concentration of revenue in glaucoma treatment, making it susceptible to changes in this specific market segment.
• High R&D expenses required to maintain innovation and advance pipeline candidates.

What Could Drive GKOS Stock Higher?

GKOS catalyst: Regulatory approval and subsequent commercial launch of iStent Infinite for refractory glaucoma, expected to significantly expand Glaukos' addressable market.

• Positive clinical trial results and regulatory submission for iDose TR, signaling progress towards a novel sustained-release drug delivery platform.
• Continued adoption and increased utilization of the iStent family of micro-bypass stents in cataract surgery globally, driven by growing awareness of MIGS benefits.
• Expansion of international sales channels and distributor networks, leading to increased market penetration in key ophthalmic markets outside the US.

What Are the Key Risks for GKOS?

Negative return on equity (-26.4%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Rich valuation — a P/E of 353.54 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Failure or delays in obtaining regulatory approvals for pipeline products like iStent Infinite and iDose TR, which are critical for future revenue growth.
• Intense competition in the ophthalmic device and pharmaceutical markets, potentially leading to pricing pressure or loss of market share.
• Negative profitability and return on equity could persist if R&D expenses remain high without a corresponding increase in commercialized product revenue.
• Dependence on physician adoption and reimbursement policies for new ophthalmic technologies, which can be subject to change and influence market uptake.
• Intellectual property challenges or patent expirations that could expose existing products to generic or biosimilar competition.

What Are the Growth Opportunities for GKOS?

• **Expansion into Refractory Glaucoma with iStent Infinite:** Glaukos' iStent Infinite, a three-stent product designed for standalone use in patients with refractory glaucoma, represents a significant growth opportunity. Refractory glaucoma patients often have limited treatment options, and a standalone MIGS procedure could offer a less invasive alternative to traditional surgeries. The global glaucoma treatment market is substantial, with the refractory segment representing a high-value, underserved population. Successful commercialization and market adoption of iStent Infinite, following regulatory approvals, could significantly expand Glaukos' addressable market beyond mild-to-moderate glaucoma, potentially within the next 2-5 years, leveraging its established expertise in micro-stent technology.
• **iDose TR for Sustained Drug Delivery:** The iDose TR, a targeted injectable implant utilizing Glaukos' micro-scale device-platform for sustained drug delivery, holds immense potential. This product aims to deliver therapeutic levels of medication over an extended period, which could improve patient adherence and reduce the burden of daily eye drop regimens, a common challenge in chronic eye disease management. The global market for ophthalmic drugs is projected to grow significantly, driven by demand for more convenient and effective treatments. Successful development and regulatory approval of iDose TR could position Glaukos as a leader in sustained-release ophthalmic therapeutics, potentially within the next 3-7 years, offering a competitive advantage in a large and growing market segment.
• **Continued Penetration in Mild-to-Moderate Open-Angle Glaucoma:** Glaukos can further capitalize on its existing iStent, iStent inject, and iStent inject W micro-bypass stents for mild-to-moderate open-angle glaucoma. As awareness and adoption of Minimally Invasive Glaucoma Surgery (MIGS) continue to grow among ophthalmologists, Glaukos is well-positioned to expand its market share. The integration of these stents into cataract surgery provides a significant procedural volume opportunity. Ongoing clinical evidence demonstrating long-term efficacy and safety will be crucial for driving broader acceptance and increasing utilization rates among surgeons globally, ensuring sustained revenue growth in its foundational market over the next 1-3 years.
• **International Market Expansion and Distribution Network Optimization:** Glaukos currently markets its products through direct sales and distributors internationally. There is a substantial opportunity to deepen penetration in existing international markets and expand into new geographies where the prevalence of glaucoma and access to advanced medical technologies are increasing. Optimizing its distribution network, potentially by establishing more direct sales channels in high-growth regions or forging strategic partnerships, could accelerate market access and revenue growth. The global ophthalmic device market continues to expand, and effective international strategy could unlock significant untapped patient populations over the next 3-5 years.
• **Pipeline Diversification into Corneal and Retinal Diseases:** While Glaukos has primarily focused on glaucoma, its stated focus on corneal disorders and retinal diseases in its business description indicates future diversification opportunities. Developing novel therapies for these large and complex markets, leveraging its expertise in micro-scale devices and drug delivery, could open entirely new revenue streams. The markets for corneal and retinal treatments are vast and driven by conditions like macular degeneration, diabetic retinopathy, and corneal dystrophies. Successful R&D and commercialization in these areas, though a longer-term endeavor (5-10+ years), would significantly broaden Glaukos' therapeutic scope and market potential.

What Threats Does GKOS Face?

• Intense competition from larger, well-capitalized medical device and pharmaceutical companies.
• Potential for regulatory delays or failures in obtaining approvals for pipeline products.
• Reimbursement challenges or changes in healthcare policies affecting adoption of new technologies.
• Patent expirations or new competitive technologies eroding market share of existing products.
• Economic downturns impacting elective surgical procedures or healthcare spending.

What Are GKOS's Competitive Advantages?

• Proprietary micro-bypass stent technology (iStent family) for glaucoma, representing a pioneering approach in MIGS.
• Established clinical evidence and regulatory approvals for its commercialized products, creating barriers to entry for competitors.
• Strong intellectual property portfolio protecting its innovative devices and drug delivery platforms.
• Specialized direct sales force and established distribution networks providing market access and physician relationships.
• Advanced pipeline assets like iStent Infinite and iDose TR, targeting high-value, underserved patient populations with novel solutions.

What Does GKOS Do?

Glaukos Corporation, incorporated in 1998 and headquartered in San Clemente, California, operates as an ophthalmic medical technology and pharmaceutical company dedicated to developing innovative therapies for a range of ocular conditions, including glaucoma, corneal disorders, and retinal diseases. The company has established a significant presence in the glaucoma treatment market with its pioneering micro-bypass stent technology. Its flagship products include the iStent, iStent inject, and iStent inject W micro-bypass stents. These devices are designed to enhance aqueous humor outflow when inserted during cataract surgery, effectively treating mild-to-moderate open-angle glaucoma. This approach represents a minimally invasive glaucoma surgery (MIGS) paradigm, aiming to reduce intraocular pressure with a less invasive procedure compared to traditional surgeries. Beyond its commercialized stents, Glaukos maintains a robust product pipeline focused on addressing additional complex ophthalmic conditions. Key pipeline assets include iStent Infinite, a three-stent product specifically engineered for use as a standalone procedure in patients suffering from refractory glaucoma, a more severe form of the disease that often requires more aggressive intervention. Another significant pipeline candidate is iDose TR, a targeted injectable implant. This innovative device utilizes Glaukos' proprietary micro-scale device-platform to deliver therapeutic levels of medication over an extended period, potentially offering a sustained-release treatment option for various ocular conditions. The company distributes its products globally through a combination of a direct sales organization in key markets and a network of distributors internationally, ensuring broad access to its specialized ophthalmic solutions. Glaukos' strategic focus remains on advancing its portfolio to improve patient outcomes across the spectrum of eye diseases.

What Products and Services Does GKOS Offer?

• Develop and commercialize ophthalmic medical technologies and pharmaceuticals.
• Focus on treating glaucoma, corneal disorders, and retinal diseases.
• Offer iStent, iStent inject, and iStent inject W micro-bypass stents for mild-to-moderate open-angle glaucoma.
• These stents enhance aqueous humor outflow when inserted during cataract surgery.
• Have a pipeline product, iStent Infinite, for refractory glaucoma as a standalone procedure.
• Are developing iDose TR, a targeted injectable implant for sustained drug delivery.
• Market products through a direct sales organization in the US and distributors internationally.

How Does GKOS Make Money?

• Generate revenue from the sale of proprietary micro-bypass stents (iStent family) to ophthalmologists and surgical centers.
• Focus on the Minimally Invasive Glaucoma Surgery (MIGS) market, often co-performed with cataract surgery.
• Invest significantly in research and development to create novel therapies and expand their product pipeline.
• Utilize a hybrid sales model with direct sales in the United States and a network of distributors for international markets.
• Aim to develop and commercialize sustained-release drug delivery systems (e.g., iDose TR) to address chronic ophthalmic conditions.

What Industry Does GKOS Operate In?

Glaukos Corporation operates within the dynamic and specialized ophthalmic medical technology and pharmaceutical industry, a segment of the broader healthcare sector focused on eye care. This industry is characterized by continuous innovation, stringent regulatory pathways, and a significant global burden of eye diseases such, as glaucoma, cataracts, and retinal disorders. Glaukos specifically targets glaucoma, a leading cause of irreversible blindness, with its pioneering Minimally Invasive Glaucoma Surgery (MIGS) devices. The competitive landscape includes established pharmaceutical companies, large medical device manufacturers, and emerging biotech firms, all vying for market share through novel drug therapies, advanced surgical instruments, and sustained-release drug delivery systems. Glaukos differentiates itself through its micro-bypass stent technology and a pipeline focused on addressing different stages and types of glaucoma, as well as expanding into corneal and retinal diseases. The market is driven by an aging global population, increasing prevalence of chronic eye conditions, and technological advancements improving diagnostic and treatment options.

Who Are GKOS's Key Customers?

• Ophthalmologists specializing in glaucoma, cataract, corneal, and retinal surgeries.
• Surgical centers and hospitals that perform ophthalmic procedures.
• Patients suffering from mild-to-moderate open-angle glaucoma, refractory glaucoma, and other ocular conditions.
• International distributors who facilitate product sales in various global markets.

Company Profile

Glaukos Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Aliso Viejo, US. The company is led by CEO Thomas William Burns. GKOS has traded publicly since 2015.

Return on equity for Glaukos Corporation stands at -26.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.8%, showing how much profit it generates from its asset base. GKOS trades at a trailing price-to-earnings ratio of 353.54, above the Healthcare sector average of ~21.50x. A current ratio of 5.43 indicates the company holds enough short-term assets to cover its near-term obligations.

GKOS Valuation & Market Position

With a $10.1B market cap, Glaukos Corporation sits in the large-cap segment of the market. Analyst price targets span from $150.00 to $215.00, with a consensus of $190.75. At the current price of $170.38, that implies approximately 12% upside potential. Relative to its peer group, GKOS's quantitative score of 36/100 is below the peer average of 67/100.

Quarterly Financial Performance: Glaukos Corporation

Revenue for Glaukos Corporation came in at $185.6M during Q2 FY2026, a 23.3% improvement versus the preceding quarter. The company recorded a net loss of $18.4M, with diluted EPS of $-0.31. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, GKOS averaged $-0.82 in diluted EPS.

Glaukos Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 24.39 places it in the safe zone, indicating low near-term bankruptcy risk.

Glaukos Corporation has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 21.1% above estimates on average.

Over the past six months, Glaukos Corporation insiders filed 99 SEC Form 4 transactions — 47 sales and 52 purchases. On net that is roughly 273K shares acquired (about $4.8M) — insiders putting money in tends to read as conviction.

GKOS Financials

GKOS Latest News

GKOS Analyst Consensus

GKOS MoonshotScore

Latest Glaukos Corporation Analysis

Common Questions About GKOS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources